Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | ASIC1 | P78348 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28189178 | 0.80 | TP53 (0.39) | TSHRKIF11NPC1RAB9ALMNA | |
| SCHEMBL4785732 | 0.80 | MYC (0.51) | KIF11KDM4ETP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL16433917 | 0.80 | KIF11 (0.52) | TSHRKIF11ALDH1A1 | |
| SCHEMBL5953676 | 0.80 | TSHR (0.52) | TSHRKIF11NPC1RAB9ALMNA | |
| SCHEMBL28986080 | 0.80 | S1PR1 (0.47) | TSHRKIF11NPC1RAB9ALMNA | |
| SCHEMBL1623868 | 0.80 | HSD11B1 (0.46) | TSHRKIF11NPC1RAB9ALMNA | |
| SCHEMBL5598094 | 0.77 | TSHR (0.43) | TSHRKIF11NPC1RAB9ALMNA | |
| SCHEMBL2652273 | 0.77 | TSHR (0.43) | TSHRKIF11NPC1RAB9ALMNA | |
| SCHEMBL1765225 | 0.77 | LMNA (0.52) | TSHRKIF11LMNATYRKDM4E | |
| SCHEMBL5279349 | 0.76 | CA12 (0.48) | TSHRKIF11NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108727157-A | The preparation method of glucagon receptor antagonist intermediate | 大连理工大学 | 2018-11-02 | — | — | CN | claimed |
| US-11858949-B2 | Organometallic compound, organic light-emitting device including the same, and diagnostic composition including the organometallic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| EP-1354887-B1 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INST TECHNOLOGY (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1097158-B1 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INST TECHNOLOGY (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1354887-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | Massachusetts Insitute of Technology (US) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858949-B2 | Organometallic compound, organic light-emitting device including the same, and diagnostic composition including the organometallic compound | L1CAM, MEN1, LEF1 | TSHR 2462/4885KIF11 1431/4885NPC1 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.